Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•AuntMinnie
Medicare Covers Half of Radiology SaaS AI Claims, Study Finds
Medicare reimbursed only about 47% of radiology SaaS AI claims between 2018 and 2023, denying over $16 million in payments.
•AuntMinnie
General LLMs Show Promise in Detecting Critical Findings in Radiology Reports
Stanford and Mayo Clinic Arizona researchers demonstrated that LLMs like GPT-4 can categorize critical findings in radiology reports using few-shot prompting.
•Health Imaging
AI Detects Incidental Lung Nodules on Routine Chest X-Rays
AI can identify pulmonary nodules on chest X-rays, aiding early lung cancer detection even when scans are not respiratory-related.